EXECUTIVE SUMMARY

- A venous thrombosis (VTE) is a blood clot (thrombus) that forms within a vein. Most often, the blood clot develops in the deep veins of the leg or pelvis, known as deep vein thrombosis (DVT). If the clot, or a part of it, breaks off from the site of formation and travels through the circulatory system, an embolism may occur. When the clot lodges in the lung this is known as pulmonary embolism (PE), a life-threatening condition.1

- Combined, DVT and PE are estimated to be the third most common cardiovascular disorder after coronary heart disease and stroke.2 Over 750,000 DVT and PE events are estimated to occur annually in six major EU countries (France, Germany, Italy, Spain, Sweden, UK)3 and over 900,000 events occur annually in the US.4

- VTE is a serious complication after major orthopaedic surgery, such as total knee replacement or total hip replacement.5

- A DVT or PE can develop in almost anyone but common risk factors include age, prolonged immobility and a history of previous blood clots.1

- Anticoagulant treatment is the standard therapy for DVT and PE treatment, preventing new blood clots from forming and existing ones from getting any bigger.5 Anticoagulants may provide up to a three-fold reduction in the recurrence of thromboembolic events.6
What are DVT and PE?

Deep vein thrombosis

DVT results from the formation of a blood clot (thrombus) inside a deep vein, usually in the leg or pelvis, which either partially or totally blocks the flow of blood in the vein.\(^1\) It increases the risk of recurring clots and may cause serious complications such as PE or post-thrombotic syndrome (PTS).\(^1,7\) Approximately one third of patients with symptomatic DVT also develop PE.\(^8\)

Pulmonary embolism

A PE occurs when a deep vein clot, or part of it, breaks loose and travels to one of the lungs where it may block circulation. It is a serious and growing complication. PE develops suddenly, often without warning, and can be fatal in up to 30% of cases within three months.\(^9\) It is considered to be the leading cause of preventable death in hospital.\(^10\) Those who survive can be affected by permanent damage to the affected lung and other vital organs as oxygenated blood cannot be circulated.\(^11\) PE may also lead to complications such as chronic thromboembolic pulmonary hypertension (CTEPH).\(^12\)

What are the symptoms?

The majority of people with DVT do not feel any symptoms. If there are symptoms they usually occur in one leg only. People with DVT may experience swelling, pain and tenderness, prominent veins and increased skin temperature.\(^13\)

People suffering from PE may experience acute shortness of breath, chest pain, sweating and rapid heart rate.\(^13,14\)
Deep Vein Thrombosis and Pulmonary Embolism

What are the risk factors?

Although a venous blood clot can develop in almost anyone, there are a number of factors and trigger events that can increase the risk of DVT and PE, including: 1, 14–16

- Increasing age
- Prolonged immobility
- Stroke or paralysis
- Previous VTE
- Cancer and its treatment
- Major surgery
- Trauma
- Obesity
- Cardiac failure
- Pregnancy
- Venous insufficiency
  (poor circulation of the blood)

Long-term complications of DVT and PE

Many patients fully recover from DVT and PE, however there are a number of long-term complications that can cause substantial illness and pose a high economic burden on societies.

Recurrent blood clots

Once a patient has had a first DVT or PE, for most people the risk of suffering a second one is likely to always remain. 17 Up to one quarter of patients with DVT and PE will experience a recurrent clot within five years. 18 Data has shown that the risk of recurrent clots can increase cumulatively in patients who are not treated with standard therapy from 11% after one year to up to 40% after 10 years. 18

Post-thrombotic syndrome

Post-thrombotic syndrome is a common complication of DVT. It results from damage to the valves in the deep veins, causing pain, redness, and thickening of the skin. It can be debilitating and may lead to chronic leg ulceration. Up to 60% of patients with DVT develop post-thrombotic syndrome, frequently occurring within two years. 19 Graduated elastic compression stockings or pneumatic compression boots and anticoagulant therapy are often used to reduce the risk of post-thrombotic syndrome after DVT. 20

Chronic thromboembolic pulmonary hypertension

Chronic thromboembolic pulmonary hypertension is a serious complication among patients who have suffered from PE. 12 Chronic thromboembolic pulmonary hypertension is a form of high blood pressure in the blood vessels of the lungs. It can be caused by old blood clots blocking blood flow in the lungs or by the progressive narrowing of healthy blood vessels. 21 Approximately 4% of patients may develop this condition within two years of suffering from a PE. 12
DVT and PE - an increasing problem

DVT and PE are collectively estimated to be the third most common cardiovascular disorder after coronary heart disease and stroke. Over 750,000 DVT and PE events are estimated to occur annually in six major EU countries (France, Germany, Italy, Spain, Sweden, UK) and over 900,000 events occur annually in the US.

Figures for the six European countries show that venous thrombotic events kill more people than AIDS, breast cancer, prostate cancer and traffic accidents combined.

Undiagnosed DVT and PE may result in significant additional burden on healthcare systems and lead to considerable underestimation of number of events, and ultimately deaths, worldwide.

The cost of DVT and PE

The human cost of DVT and PE is immeasurable and has significant implications on patients’ lives, their families, healthcare systems and society as a whole.

Given their prevalence, associated morbidity, mortality and chronic complications, DVT and PE are costly conditions that put a considerable burden on healthcare systems worldwide. Annual costs are estimated to be more than €3.07 billion in Europe for total direct costs associated with DVT and PE, and up to $15.5 billion in the US for DVT and PE diagnosis and treatment.
Current management of DVT and PE

There are treatment options for people at every stage of DVT and PE:
- Protection from an initial clot, known as primary prevention
- Treating a clot that has already developed
- Prevention against recurrent clots, known as secondary prevention and long-term treatment

Primary prevention of VTE – prevention of a first event

The latest guidelines from the American College of Chest Physicians (ACCP) provide extensive recommendations for the primary prevention of VTE in several patient groups including:5, 24
- Patients undergoing orthopaedic surgery (e.g. of the hip or knee)
- Non-orthopaedic surgery patients (e.g. patients undergoing general, GI, urological, gynaecologic, bariatric, vascular, plastic, or reconstructive surgery)
- Non-surgical patients (e.g. critically ill medical patients, patients with cancer, those chronically immobilised, people who travel long-distances)

Recommendations for patients undergoing orthopaedic surgery

VTE is a common complication associated with major orthopaedic surgery. Anticoagulation therapy is effective in preventing venous blood clots in patients undergoing total knee replacement or total hip replacement. The ACCP CHEST guidelines highlight the benefits of one of the following treatments:5,24
- Novel oral anticoagulants e.g dabigatran etexilate, rivaroxaban or apixaban
- Low-molecular weight heparin (LMWH)
- Low-dose unfractionated heparin (LDUH)
- Fondaparinux
- Adjusted-dose vitamin K antagonist (VKA)
- Acetylsalicylic acid (ASA)
- An intermittent pneumatic compression device
Dabigatran etexilate, a direct thrombin inhibitor, was the first approved treatment of a new generation of novel oral anticoagulants. Direct thrombin inhibitors work by specifically and selectively blocking the activity of thrombin – the central enzyme in clot formation.\textsuperscript{25, 26}

In 2008 the European Commission granted EU approval for dabigatran etexilate for the primary prevention of VTE in adults who have undergone elective total knee or hip replacement surgery.\textsuperscript{27} Results from the RE-NOVATE\textsuperscript{E28}, RENOVATE II\textsuperscript{E29} and RE-MODEL\textsuperscript{TM30} trials show that dabigatran etexilate is as effective as enoxaparin, a low-molecular weight heparin, in preventing VTE events and their consequences after total knee or hip replacement. In addition, treatment with dabigatran etexilate resulted in a low incidence of major bleeding events.\textsuperscript{28-30}

**Recommendations for non-surgical patients and patients undergoing non-orthopaedic surgery**

Treatment recommendations for other patients depend on the respective patient type, surgery type and the presence of risk factors for both thrombosis and bleeding. Treatment options include anticoagulant therapy e.g. low-molecular-weight heparin (LMWH), low-dose unfractionated heparin (LDUH) or fondaparinux, elastic compression stockings or pneumatic compression devices, or no treatment at all.\textsuperscript{24}

**DVT and PE treatment**

Data has shown that up to 30% of people who experience a PE die within three months.\textsuperscript{9} Immediate treatment is therefore crucial. There are different treatment options for DVT and PE. Usually, initial therapy is started with an injectable and fast-acting anticoagulant, which is then followed by an oral anticoagulant. In case of major PE, systemic thrombolysis can also be considered.\textsuperscript{5, 24}

The ACCP CHEST guidelines recommend anticoagulation treatment with LMWH, fondaparinux or unfractioned heparin. Additionally, an oral VKA should be introduced on the first day of treatment. The parallel treatment should continue for a minimum of five days and until the patients' blood levels show that the appropriate therapeutic level for VKA (international normalised ratio between 2 and 3) has been achieved.\textsuperscript{31} In addition, the ACCP CHEST guidelines highlight that treatment of DVT and PE with a novel oral anticoagulant such as dabigatran, in addition to being less burdensome to patients, may prove to be associated with better clinical outcomes than VKA and LMWH therapy.\textsuperscript{31}

Treatment duration is typically for three months. Factors that impact management and treatment duration include:

- Severity of symptoms
- Location and extension of DVT (above or below the knee)
- Presence of risk factors for thrombosis including prior DVT or PE
- Presence of risk factors for bleeding
- Contraindications to treatment

For patients with DVT, compression stockings are also recommended to help prevent post thrombotic syndrome.\textsuperscript{31}

In June 2014, dabigatran etexilate was approved by the European Commission for the treatment and prevention of recurrence of DVT and PE.\textsuperscript{27} The U.S. Food and Drug Administration (FDA) approved dabigatran etexilate for DVT and PE patients in April 2014.\textsuperscript{32} The approvals were based on results from three robust phase III clinical trials that demonstrated the efficacy of dabigatran etexilate in the treatment and prevention of repeat DVT and PE compared to warfarin (RE-COVER\textsuperscript{TM}, RE-COVER II\textsuperscript{TM}, RE-MEDY\textsuperscript{TM}) and one trial compared to placebo (RE-SONATE\textsuperscript{TM}), involving close to 10,000 patients.\textsuperscript{33-35} Data also showed that treatment with dabigatran etexilate had significantly lower bleeding rates compared to warfarin.\textsuperscript{33-35}
Prevention of recurrent DVT and PE, or secondary prevention and long-term treatment

Data has shown that the risk of recurrent DVT and PE can increase cumulatively in patients who are not treated with standard therapy from 11% after one year to up to 40% after 10 years. Therefore, long-term prevention is essential. Within the first two years, the risk of recurrence is greatest. Treatment duration is often between three and six months, but due to the high likelihood of DVT and PE recurrence, long-term anticoagulant treatment beyond three months should be considered in patients who are at risk. Treatment decisions should be tailored to the patient and their individual risk factors, and physicians should weigh up the benefit-risk profile of extended treatment versus the risk of bleeding on a regular basis.

Risk factors for a recurrent DVT and PE include:
- Number of previous DVT and PE events
- Location of initial DVT and PE
- Original trigger event (unprovoked or not)
- Patient characteristics including age, sex and weight

The availability of novel oral anticoagulants that – in contrast to traditional vitamin K antagonists – do not require regular blood testing and are not associated with numerous limitations like food-interactions or drug-interactions, may help to improve long-term treatment to better prevent recurrent events.

Deep Vein Thrombosis and Pulmonary Embolism
References

8. White RH. The Epidemiology of Venous Thromboembolism Circulation. 2003;107;3-4-18